NCT00006484已完成3 期
Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 185
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
详细描述
OBJECTIVES:
- Compare the effects of paclitaxel and carboplatin with or without tirapazamine on progression-free survival and overall survival in patients with stage IV and selected stage IIIB non-small cell lung cancer.
- Compare response rates in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to weight loss (less than 5% vs 5% or more), stage of disease (IIIB vs IV), and lactate dehydrogenase level (normal vs abnormal). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive tirapazamine IV over 2 hours followed by paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
- Arm II: Patients receive paclitaxel and carboplatin as in arm I. Treatment continues every 21 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for one year, and then every 6 months for 2 years, or until death.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically proven newly diagnosed advanced primary non-small cell lung cancer (NSCLC), including the following cellular types:
- •Adenocarcinoma
- •Large cell carcinoma
- •Squamous cell carcinoma
- •Unspecified carcinoma OR
- •Recurrent disease after prior surgery and/or radiotherapy
- •Stage IIIB disease
- •T4 lesion due to malignant pleural effusion OR
- •Stage IV disease
- •Any T, any N, M1 (distant metastasis, including lesions in multiple lobes of the ipsilateral lung)
- •Measurable or evaluable disease
- •Pleural effusions, ascites, and laboratory parameters not considered as only evidence of disease
- •Must be outside prior radiated field or area of prior surgical resection or new lesion must be present
- •No known brain metastases
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Zubrod 0-1
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute granulocyte count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Hemoglobin at least 9 g/dL
- •Bilirubin no greater than 2 times upper limit of normal (ULN)
- •SGOT or SGPT no greater than 2 times ULN
- •Alkaline phosphatase no greater than 2 times ULN
- •Creatinine no greater than ULN
- •Creatinine clearance at least 50 mL/min
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No peripheral neuropathy (motor or sensory) of grade 2 or greater
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I/II cancer in complete remission
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •No prior biologic therapy for NSCLC
- •Chemotherapy:
- •No prior systemic chemotherapy for NSCLC
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •See Disease Characteristics
- •At least 3 weeks since prior radiotherapy and recovered
- •No concurrent radiotherapy
- •See Disease Characteristics
- •At least 2 weeks since prior thoracic or other major surgery and recovered
排除标准
- 未提供
研究者
研究点 (185)
Loading locations...
相似试验
已完成
3 期
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian CancerOvarian CancerNCT00003644Gynecologic Oncology Group571
Unknown
3 期
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung CancerLung CancerNCT00039039IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy300
已完成
2 期
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced ThymomaThymomaThymic CarcinomaNCT00010257Eastern Cooperative Oncology Group46
已完成
2 期
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal CancerHead and Neck CancerNCT00003206Eastern Cooperative Oncology Group
撤回
3 期
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical CancerCervical CancerNCT00057928SWOG Cancer Research Network